Abstract
High dose intravenous immunoglobulins (IVIG) are important agents in the treatment of numerous diseases in rheumatology and dermatology. Because the diseases treated with IVIG are rare, their use is mostly not based on controlled randomized trials. Since the high costs of therapy often prohibit the use of IVIG as first line therapy and as there are no guidelines on the use of IVIG in dermatologic diseases, a consensus conference was held in Wiesbaden, Germany, to address these issues. This manuscript documents the expert consensus on the use of IVIG in dermatology and reflects current clinical practice. It should be a guideline for the practitioner for the use of IVIG in dermatologic diseases.
| Translated title of the contribution | High dose intravenous immunoglobulin therapy: Dermatologic applications |
|---|---|
| Original language | German |
| Journal | JDDG - Journal of the German Society of Dermatology |
| Volume | 1 |
| Issue number | 3 |
| Pages (from-to) | 183-190 |
| Number of pages | 8 |
| ISSN | 1610-0379 |
| DOIs | |
| Publication status | Published - 01.03.2003 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'High dose intravenous immunoglobulin therapy: Dermatologic applications'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver